Baxter Healthcare Pty Limited v Australian Competition and Consumer Commission & Ors

Baxter Healthcare Pty Limited appealed to the High Court of Australia against a decision of the Full Federal Court which had upheld a finding by the Australian Competition and Consumer Commission (ACCC) that Baxter had engaged in conduct that contravened section 47(1) of the *Trade Practices Act 1974* (Cth) (the Act). The ACCC had alleged that Baxter had engaged in exclusive dealing by supplying its intravenous (IV) solutions and administration sets to hospitals on the condition that those hospitals would not acquire similar products from Baxter's competitors.

The central legal issue before the High Court was whether Baxter's conduct constituted exclusive dealing within the meaning of section 47(1) of the Act. Specifically, the Court had to determine whether Baxter had supplied goods to a person (hospitals) for the purpose of, or likely to have the effect of, substantially lessening competition in a market in which Baxter supplied goods, by requiring or inducing that person not to acquire goods of that kind from another person. The Court also considered whether the Full Federal Court had erred in its interpretation of the relevant provisions of the Act and the evidence presented.

The High Court, in a joint judgment, found that Baxter's conduct did not contravene section 47(1) of the Act. Their Honours reasoned that the evidence did not establish that Baxter's conduct had the purpose or effect of substantially lessening competition. The Court emphasised that the mere fact that Baxter secured a significant market share through its supply agreements did not, in itself, demonstrate a substantial lessening of competition. The Court applied the principles of statutory interpretation to section 47(1), focusing on the need for a demonstrable impact on competition rather than simply the existence of exclusive arrangements.

The appeal was allowed, and the orders of the Full Federal Court were set aside.